Dr. Jonathan Trent on FDA Approval of Trabectedin for Soft Tissue Sarcomas

14 Görünümler
administrator
administrator
07/18/23

Jonathan C. Trent, MD, professor of Medicine, co-director, Musculoskeletal Center, Sarcoma Medical Research Program, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the FDA approval of trabectedin for patients with soft tissue sarcomas.

  • kategori

Daha fazla göster

0 Yorumlar Göre sırala

Hiçbir yorum bulunamadı

Facebook Yorumları

Bir sonraki